RxDoctor Payments Data

Raminder Singh, MD

Cardiovascular Disease · Elgin, ILNPI 1609847599

Payments from drug & device makers

$19,090in general payments, 2019–2025

Across 202 payments — averaging $94.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$7K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Amgen$3K
  • Johnson & Johnson$2K
  • Abbott$480
  • E.r. Squibb & Sons, L.L.C.$326
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$1,8009%
  • Speaking & faculty fees$10,31454%
  • Travel & lodging$1,0846%
  • Food & beverage$5,87631%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,090 in reported general payments places this provider in the 80th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$277,782
Medicare patients
1,177
Services billed
2,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$236,211
XareltoRivaroxaban205$225,815
JardianceEmpagliflozin83$112,586
Repatha SureclickEvolocumab76$42,377
EntrestoSacubitril/Valsartan33$42,363
Praluent PenAlirocumab17$12,224
Metoprolol Succinate364$6,300
Atorvastatin Calcium565$6,129
Rosuvastatin Calcium377$5,848
Ezetimibe184$4,923
Nifedipine ErNifedipine158$4,849
Losartan Potassium302$2,707
Potassium Chloride90$2,162
Metoprolol Tartrate165$1,743
Carvedilol177$1,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$236,211226 claims
Johnson & JohnsonXarelto$1,785$225,815205 claims
Boehringer IngelheimJardiance$151$112,58683 claims
NovartisEntresto$297$42,36333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →